RIGHT Choice
RIGHT Choice: Subgroup Analyses From the Phase II Trial of First-line Ribociclib + ET vs Combination Chemotherapy in Clinically Aggressive HR+/HER2- Advanced Breast Cancer

Released: December 18, 2024

Expiration: June 17, 2025

Activity

Progress
1
Course Completed